Ironwood Pharmaceuticals Inc/ US46333X1081 /
2024-09-19 10:00:00 PM | Chg. -0.0100 | Volume | Bid12:55:39 AM | Ask12:55:39 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
4.5100USD | -0.22% | 1.31 mill. Turnover: 4.68 mill. |
4.4900Bid Size: 600 | 4.6000Ask Size: 500 | 720.42 mill.USD | - | - |
Assets
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Property and Equipment | 12.4290 | 8.9290 | 7.5750 | 6.2880 | 5.5850 | ||||||
Intangible Assets | - | - | - | - | 3.6820 | ||||||
Long-Term Investments | - | - | - | - | - | ||||||
Fixed Assets | 95.8960 | 63.3990 | 381.7020 | 319.8930 | 237.7850 | ||||||
Inventories | .6480 | - | - | - | - | ||||||
Accounts Receivable | 11.2790 | 122.3510 | 114.0420 | 115.4580 | 129.1220 | ||||||
Cash and Cash Equivalents | 177.0230 | 362.5640 | 620.1290 | 656.2030 | 92.1540 | ||||||
Current Assets | 306.8520 | 495.8390 | 745.2250 | 780.6260 | 233.2880 | ||||||
Total Assets | 402.7480 | 559.2380 | 1,126.9270 | 1,100.5190 | 471.0730 |
Liabilities
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Accounts Payable | 3.9780 | .6610 | .9350 | .4830 | 7.8300 | ||||||
Long-term debt | 407.9940 | 430.2560 | 337.3330 | 396.2510 | 498.3090 | ||||||
Liabilities to Banks | - | - | - | - | - | ||||||
Provisions | - | - | - | - | - | ||||||
Liabilities | 495.9990 | 496.5980 | 521.0160 | 448.1410 | 817.3680 | ||||||
Share Capital | .1580 | .1610 | .1620 | .1540 | .1560 | ||||||
Total Equity | -93.2510 | 62.6400 | 605.9110 | 652.3780 | -346.2950 | ||||||
Minority Interests | - | - | - | - | 0.0000 | ||||||
Total liabilities equity | 402.7480 | 559.2380 | 1,126.9270 | 1,100.5190 | 471.0730 |
Income Statement
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 428.4130 | 389.5230 | 413.7530 | 410.5960 | 442.7350 | ||||||
Depreciation (total) | - | - | - | - | - | ||||||
Operating Result | 120.1230 | 142.9400 | 232.2590 | 250.3370 | -945.4300 | ||||||
Interest Income | -36.6020 | -29.4780 | -31.1500 | -7.5980 | -21.6290 | ||||||
Income Before Taxes | - | 108.8610 | 200.6570 | 252.4220 | -948.0690 | ||||||
Income Taxes | - | 2.6850 | 327.7910 | -77.3570 | -83.4900 | ||||||
Minority Interests Profit | - | - | - | - | -29.3200 | ||||||
Net Income | 21.5050 | 106.1760 | 528.4480 | 175.0650 | -1,002.2390 |
Per Share
Cash Flow
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Cash Flow from Operating Activities | 10.7250 | 168.8360 | 261.8950 | 273.7630 | 183.4270 | ||||||
Cash Flow from Investing Activities | -11.1440 | -1.8420 | -.2650 | -.1360 | -1,026.3180 | ||||||
Cash Flow from Financing | -1.1850 | 18.5460 | -4.5500 | -237.5530 | 277.1600 | ||||||
Decrease / Increase in Cash | -1.6040 | 185.5400 | 257.0800 | 36.0740 | -565.7840 | ||||||
Employees | - | - | - | - | - |